Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash & Equivalents: 2020-2024

Historic Cash & Equivalents for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to $71.3 million.

  • Arcutis Biotherapeutics' Cash & Equivalents fell 65.06% to $47.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.1 million, marking a year-over-year decrease of 65.06%. This contributed to the annual value of $71.3 million for FY2024, which is 19.30% down from last year.
  • As of FY2024, Arcutis Biotherapeutics' Cash & Equivalents stood at $71.3 million, which was down 19.30% from $88.4 million recorded in FY2023.
  • Arcutis Biotherapeutics' 5-year Cash & Equivalents high stood at $96.4 million for FY2021, and its period low was $53.6 million during FY2022.
  • Moreover, its 3-year median value for Cash & Equivalents was $71.3 million (2024), whereas its average is $71.1 million.
  • In the last 5 years, Arcutis Biotherapeutics' Cash & Equivalents crashed by 44.38% in 2022 and then spiked by 64.80% in 2023.
  • Over the past 5 years, Arcutis Biotherapeutics' Cash & Equivalents (Yearly) stood at $65.1 million in 2020, then spiked by 48.20% to $96.4 million in 2021, then slumped by 44.38% to $53.6 million in 2022, then soared by 64.80% to $88.4 million in 2023, then decreased by 19.30% to $71.3 million in 2024.